Nutriband is a small, pre-commercial pharmaceutical development company focused on transdermal (skin patch) drug delivery. Its core asset is AVERSA, a proprietary abuse-deterrent technology that adds aversive agents to the backing of existing approved drug patches, making them unpleasant to abuse via oral, buccal, or inhalation routes — which account for roughly 70% of fentanyl patch abuse — without interfering with normal therapeutic delivery. The lead product, AVERSA Fentanyl, is an abuse-deterrent version of an already-approved generic fentanyl patch. Because fentanyl's safety and efficacy are established, Nutriband is pursuing FDA approval via the 505(b)(2) pathway, which primarily requires a single Phase 1 Human Abuse Potential clinical study rather than full Phase 2/3 trials. No abuse-deterrent transdermal patch has ever been approved anywhere in the world. Nutriband has a partnership with Kindeva Drug Delivery (formerly 3M Drug Delivery) to co-develop AVERSA Fentanyl, with shared development costs in exchange for milestone payments. Beyond fentanyl, Nutriband is developing AVERSA versions of buprenorphine and methylphenidate along the same regulatory path. While the pipeline advances, Nutriband generates current revenue through two contract services subsidiaries: Pocono Pharmaceuticals, a contract manufacturer for health and OTC products, and 4P Therapeutics, a CRO providing early-stage drug development and regulatory consulting services. These subsidiaries fund day-to-day operations but are not the primary value driver. If AVERSA Fentanyl is approved, Nutriband plans to commercialize it as a branded prescription product, with commercial success depending on prescriber adoption and insurance reimbursement.